GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (OTCPK:PAIOF) » Definitions » Investments And Advances

Paion Ag (Paion Ag) Investments And Advances : $0.00 Mil (As of Jun. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Paion Ag Investments And Advances?

Paion Ag's Investments And Advances for the quarter that ended in Jun. 2023 was $0.00 Mil.


Paion Ag Investments And Advances Historical Data

The historical data trend for Paion Ag's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paion Ag Investments And Advances Chart

Paion Ag Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Paion Ag Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Paion Ag Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Paion Ag (Paion Ag) Business Description

Traded in Other Exchanges
Address
Heussstrasse 25, Aachen, DEU, 52078
Paion Ag is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.